Estrogen Receptor Beta Partial Agonist for Gynecological Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for estrogen-dependent gynecological diseases like endometriosis, uterine fibroids, and uterus adenomyosis are limited by side effects, short duration of use, and inability for long-term administration due to bone mineral loss and ovarian dysfunction, with existing drugs either causing uterine cancers or having low absorption and short half-life.
Innovation Solution
A compound acting as an estrogen receptor α-inhibiting β partial agonist, represented by the formula (a), which is orally active, stable, and has anti-proliferative effects on ectopic endometrial tissue, allowing for safe and effective long-term treatment of these diseases with low toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tamoxifen is used to inhibit estrogen receptor binding, then breast cancer treatment is effective, but it causes uterine body cancer, uterine sarcoma or endometriosis due to endogenous partial agonistic action
Solution Approach 1:
The compound exhibits tissue-selective pharmacological activity: it acts as an antagonist at estrogen receptor α in the uterus (inhibiting endometrial tissue growth) while acting as a partial agonist at estrogen receptor β in the bone (maintaining bone mass). This local quality differentiation resolves the contradiction by providing cancer prevention in the uterus without causing the harmful uterine side effects associated with tamoxifen.
2Reliability
If fulvestrant is used as a therapeutic agent for breast cancer, then it does not provide endogenous partial agonist action to the estrogen receptor, but it has low gastrointestinal absorption rate and short half-life requiring intramuscular injection
Solution Approach 1:
The compound possesses optimized pharmacokinetic parameters including high oral bioavailability and long half-life, allowing for convenient oral administration once or twice weekly. This parameter optimization resolves the contradiction by maintaining effective breast cancer treatment while eliminating the need for invasive intramuscular injections required by fulvestrant.
3Reliability
If raloxifene is used for osteoporosis treatment, then bone mass increases by estrogen receptor partial agonist activity, but it cannot be used for treating estrogen-dependent gynecological diseases
Solution Approach 1:
The compound demonstrates differential tissue selectivity: it acts as a partial agonist at estrogen receptor β in bone tissue (increasing bone mass for osteoporosis treatment) while acting as an antagonist at estrogen receptor α in uterine tissue (inhibiting endometrial tissue growth for gynecological disease treatment). This local quality differentiation resolves the contradiction by enabling dual therapeutic applications that raloxifene cannot achieve.
4Reliability
If gonadotropin agonist is used for gynecological disease treatment, then it can treat the diseases, but the administration period is restricted due to side effects such as bone mineral loss and ovarian dysfunction
Solution Approach 1:
The compound provides sustained therapeutic efficacy with a long half-life, enabling long-term administration (months to years) without the bone mineral loss and ovarian dysfunction side effects that limit gonadotropin agonist therapy to short durations. This parameter change in both pharmacokinetics and safety profile resolves the contradiction by extending the feasible administration duration.
Data Source
AI summary
[Problem] To provide a therapeutic agent for estrogen-dependent gynecological diseases such as endometriosis, uterine fibroids, and uterus adenomyosis. [Solution] To use an estrogen receptor α-inhibiting β partial agonist represented by the formula (a), a pharmaceutically-acceptable salt thereof, or a hydrate of either of the afore-mentioned, as an active ingredient.